Stay updated on 2-Dose IV Mg vs 1-Dose+Budesonide in Severe Asthma Clinical Trial
Sign up to get notified when there's something new on the 2-Dose IV Mg vs 1-Dose+Budesonide in Severe Asthma Clinical Trial page.

Latest updates to the 2-Dose IV Mg vs 1-Dose+Budesonide in Severe Asthma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page revision tag was updated from v3.4.0 to v3.4.1. This appears to be a minor version update that does not alter study content or user-facing features.SummaryDifference0.1%

- Check27 days agoChange DetectedShow glossary option added; metadata labels updated (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and a new revision tag v3.4.0 replacing v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page shows a new revision label (v3.3.4) replacing the previous v3.3.3. This appears to be a minor backend/content update with no effect on study details or user interactions.SummaryDifference0.1%

- Check49 days agoChange DetectedSponsor information updated to Hamad Medical Corporation. Recruitment/status metadata added (Last known status was 2023-12; Verified).SummaryDifference0.4%

- Check63 days agoChange DetectedRevision note 'Revision: v3.3.3' was added to the page footer, and the 'HHS Vulnerability Disclosure' link along with the older 'Revision: v3.3.2' reference were removed. These are minor site maintenance updates that do not alter the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to 2-Dose IV Mg vs 1-Dose+Budesonide in Severe Asthma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 2-Dose IV Mg vs 1-Dose+Budesonide in Severe Asthma Clinical Trial page.